Oral Session 2-11B AML: Novel therapeutic targets

[OS2-11B-1] Phase 1 study of guadecitabine (SGI-110) in Japanese patients with acute myeloid leukemia

Tomoko Hata¹, Masafumi Taniwaki², Toru Sakura³, Toshihiro Miyamoto⁴, Kensuke Usuki⁵, Shinji Tetsuo⁶, Ei Leen Liew⁷, Kiyohiko Hatake⁸ (1.Dept. of Hematology, Nagasaki University Hospital, Nagasaki, Japan, 2.Kyoto Prefectural University of Medicine, Kyoto, Japan, 3.Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan, 4.Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan, 5.Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan, 6.Department of Clinical Management, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan, 7.Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan, 8.Department of Hematology, International University of Health and Welfare, Tokyo)